MAP3K1 Mutations Confer Tumor Immune Heterogeneity in Hormone Receptor-Positive HER2-Negative Breast Cancer

By
Emily Salmini
-
0
50
The authors performed a multi-omics analysis of a large cohort of HR+/HER2- breast cancer patients and revealed that HR+/HER2- breast cancer possessed a highly heterogeneous tumor immune microenvironment.
[Journal of Clinical Investigation]
Abstract